These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33083254)

  • 1. Antihepatic Fibrosis Drugs in Clinical Trials.
    Guo YC; Lu LG
    J Clin Transl Hepatol; 2020 Sep; 8(3):304-312. PubMed ID: 33083254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis in alcoholic liver disease.
    Bataller R; Gao B
    Semin Liver Dis; 2015 May; 35(2):146-56. PubMed ID: 25974900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
    Tanwar S; Rhodes F; Srivastava A; Trembling PM; Rosenberg WM
    World J Gastroenterol; 2020 Jan; 26(2):109-133. PubMed ID: 31969775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal and Organoid Models of Liver Fibrosis.
    Bao YL; Wang L; Pan HT; Zhang TR; Chen YH; Xu SJ; Mao XL; Li SW
    Front Physiol; 2021; 12():666138. PubMed ID: 34122138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.
    Hasegawa T; Yoneda M; Nakamura K; Makino I; Terano A
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1667-72. PubMed ID: 11564008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.
    Lemoinne S; Friedman SL
    Curr Opin Pharmacol; 2019 Dec; 49():60-70. PubMed ID: 31590120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
    Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
    Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
    Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
    J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis: Common mechanisms and antifibrotic therapies.
    Schuppan D
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S51-9. PubMed ID: 26189980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases.
    Eguchi A; Feldstein AE
    Liver Res; 2018 Mar; 2(1):30-34. PubMed ID: 30345152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the recent advances in antifibrotic therapy.
    Tacke F; Weiskirchen R
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1143-1152. PubMed ID: 30261763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.
    Diwan R; Gaytan SL; Bhatt HN; Pena-Zacarias J; Nurunnabi M
    Drug Deliv Transl Res; 2024 Mar; ():. PubMed ID: 38446352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcoholic steatohepatitis.
    Susca M; Grassi A; Zauli D; Volta U; Lenzi M; Marchesini G; Bianchi FB; Ballardini G
    Dig Liver Dis; 2001 Dec; 33(9):768-77. PubMed ID: 11838612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
    Nishikawa K; Osawa Y; Kimura K
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron and liver fibrosis: Mechanistic and clinical aspects.
    Mehta KJ; Farnaud SJ; Sharp PA
    World J Gastroenterol; 2019 Feb; 25(5):521-538. PubMed ID: 30774269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.
    Rockstroh JK
    Curr HIV/AIDS Rep; 2017 Apr; 14(2):47-53. PubMed ID: 28284005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Interleukin-20 Cytokine Family in Liver Disease.
    Caparrós E; Francés R
    Front Immunol; 2018; 9():1155. PubMed ID: 29892294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.